B-Cell Non-Hodgkin Lymphoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis 1
Delveinsight Business Research LLP
“B-Cell Non-Hodgkin Lymphoma Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the B-Cell Non-Hodgkin Lymphoma Market.

The B-Cell Non-Hodgkin Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the B-Cell Non-Hodgkin Lymphoma pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, B-Cell Non-Hodgkin Lymphoma collaborations, mergers, acquisition, funding, designations, and other product-related details.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight

B-Cell Non-Hodgkin Lymphoma Pipeline Analysis

The dynamics of the B-cell NHL market is anticipated to change in the coming years owing to the launch of emerging therapies during the forecast period. Major Pharma giants are thoroughly working toward the development of new treatment therapies for this indication, in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with B-cell NHL.

B-Cell Non-Hodgkin Lymphoma Companies:
BeiGene
Pfizer
Merck
AbbVie
Roche
Epizyme
Novartis
Verastem
Gilead Sciences
AstraZeneca
Merck Sharp & Dohme
Bristol-Myers Squibb
Gilead Sciences
MorphoSys AG
TG Therapeutics
Hoffmann-La Roche
Pharmacyclics
AbbVie Company
Celgene Corporation
Genentech (Roche Group)
Xynomic Pharmaceuticals
Spectrum Pharmaceuticals
Millennium Pharmaceuticals
And many others.

B-Cell Non-Hodgkin Lymphoma Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of B-Cell Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the B-Cell Non-Hodgkin Lymphoma Treatment.

  • B-Cell Non-Hodgkin Lymphoma key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • B-Cell Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the B-Cell Non-Hodgkin Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

B-Cell Non-Hodgkin Lymphoma Therapies covered in the report include:
Avelumab
KTE-X19
Tafasitamab
Abexinostat
Tazemetostat
Umbralisib
Lisocabtagene maraleucel
Brukinsa (Zanubrutinib)
Polivy (Polatuzumab vedotin)
Venetoclax (ABT199)
Kymriah (tisagenlecleucel)
Copiktra (Duvelisib)
Imbruvica (Ibrutinib)
Zydelig (Idelalisib)
Revlimid (lenalidomide)
Keytruda (Pembrolizumab)
Aliqopa (Copanlisib; BAY 80-6946)
Yescarta (Axicabtagene ciloleucel; KTE-C19)
Calquence (Acalabrutinib)
Gazyva (Obinutuzumab, GA-101)
Velcade (bortezomib)
And many more.

Owing to the launch of upcoming therapies, the B-Cell Non-Hodgkin Lymphoma market size shall increase significantly during the forecast period.

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for B-Cell Non-Hodgkin Lymphoma.    

  • In the coming years, the B-Cell Non-Hodgkin Lymphoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 

  • The companies and academics are working to assess challenges and seek opportunities that could influence B-Cell Non-Hodgkin Lymphoma Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  • A detailed portfolio of major pharma players who are involved in fueling the B-Cell Non-Hodgkin Lymphoma treatment market. Several potential therapies for B-Cell Non-Hodgkin Lymphoma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the B-Cell Non-Hodgkin Lymphoma market size in the coming years.  

  • Our in-depth analysis of the B-Cell Non-Hodgkin Lymphoma pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

Table of Content

1. Report Introduction

2. B-Cell Non-Hodgkin Lymphoma 

3. B-Cell Non-Hodgkin Lymphoma Current Treatment Patterns

4. B-Cell Non-Hodgkin Lymphoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. B-Cell Non-Hodgkin Lymphoma Late Stage Products (Phase-III)

7. B-Cell Non-Hodgkin Lymphoma Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. B-Cell Non-Hodgkin Lymphoma Discontinued Products

13. B-Cell Non-Hodgkin Lymphoma Product Profiles

14. B-Cell Non-Hodgkin Lymphoma Key Companies

15. B-Cell Non-Hodgkin Lymphoma Key Products

16. Dormant and Discontinued Products

17. B-Cell Non-Hodgkin Lymphoma Unmet Needs

18. B-Cell Non-Hodgkin Lymphoma Future Perspectives

19. B-Cell Non-Hodgkin Lymphoma Analyst Review  

20. Appendix

21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight

Latest Reports By DelveInsight –

B-Cell Non-Hodgkin Lymphoma Market
DelveInsight’s “B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology and Market Forecast – 2030” report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma Market size and shares analysis for the 7MM (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Anti-hypertension Market
DelveInsight’ s “Anti-hypertension Market Insights, Epidemiology, and Market Forecast 2030” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Anti-hypertension market size, share, trends, growth and forecast for the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/